Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03625557
Other study ID # 01-MX-002
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 30, 2019
Est. completion date April 16, 2020

Study information

Verified date April 2020
Source Guardant Health, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

To document the clinical outcomes of cancer patients who received the Guardant360® test and agree to share their records with Guardant Health.


Description:

This is an observational study of clinical outcomes to be conducted in the United States. Patients with a diagnosis of Stage 3-4 advanced cancer who possess specific pathway mutations identified by the Guardant360® test will be eligible to enroll in the study. Patients will be recruited by telephone or email and/or through the Guardant Health Patient Portal to determine interest in the study. Should patients be interested in contributing to this registry study, they will be prompted to consent via a commercial service for patients to request, manage, and view their medical records. Enrolled participants will be requested to release copies of their medical records for review by the principal investigator. Study adminsitrators will abstract participant demographics, cancer-related therapies, and clinical outcomes for analysis.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date April 16, 2020
Est. primary completion date February 1, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility General Inclusion Criteria:

- Adults (= 18 years old) with a diagnosis of Stage 3 or Stage 4 cancer (non-hematologic malignancy). Patients with advanced cancers not typically staged 1-4 (such as extensive stage small lung cancer) may be enrolled.

- Results from Guardant360® test

- Patient has previously provided contact information (either email or phone) to Guardant Health.

- Able and wiling to complete the informed consent process.

- Willingness to consent to the release of medical records.

- Willingness to provide Medical Records Release

General Exclusion Criteria:

- Unwilling or unable to provide written informed consent.

- Unable to understand English.

- Diagnosis of NSCLC

- Guardant 360® test results released to the patient's physician no less than 14 days and no greater than 60 days prior to initial patient contact.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Guardant Health Redwood City California

Sponsors (1)

Lead Sponsor Collaborator
Guardant Health, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective response rate (ORR) Portion of patients with tumors that are found to have complete or partial response 3 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05077384 - Open-label Study of Surufatinib in Japanese Patients Phase 1/Phase 2
Completed NCT02412722 - A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies Phase 1
Recruiting NCT04285242 - Metabolic and Immunological Phenotyping in Patients With Cancer
Not yet recruiting NCT05968170 - TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant N/A